Company profile: Nanna Therapeutics
1.1 - Company Overview
Company description
- Provider of drug discovery platforms targeting fundamental cellular processes in age-related diseases. Offers the Nanoscale Medicines Discovery Engine for novel drugs addressing mitochondrial dysfunction and the Totally Integrated Medicines Engine (TIME), conducting 100 million phenotypic assays per hour to identify small-molecule leads for mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases and cancer.
Products and services
- Totally Integrated Medicines Engine (TIME): A high-throughput discovery platform executing 100 million phenotypic assays per hour to pinpoint novel small-molecule lead compounds for age-related disease targets
- Nanoscale Medicines Discovery Engine: A mechanism-driven platform that discovers novel drugs addressing age-related diseases arising from mitochondrial dysfunction by targeting fundamental cellular processes
- Age-Related Disease Drug Discovery Programs: Pathway-centric discovery campaigns targeting fundamental cellular processes across mitochondrial, neurodegenerative, cardiovascular, metabolic, joint/tissue diseases and cancer to create effective therapeutic drugs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nanna Therapeutics
Evitria
HQ: Switzerland
Website
- Description: Provider of global antibody expression services specialized in CHO-based transient production of recombinant antibodies, including chimeric, bispecific, Fc-optimized, fusion, afucosylated (GlymaxX) and Fc-silenced (STR) variants. Offers bispecific formats (Duobody, IgG-scFvs, Knobs-into-Holes) and transient expression of secreted proteins (scFvs, extracellular domains, cytokines, viral proteins).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evitria company profile →
AHN Biotechnologie
HQ: Germany
Website
- Description: Provider of plastic laboratory articles for molecular-biological, biochemical, cellbiological and pharmaceutical research, including innovative precision pipette tips, precision filter tips and modern micropipettes, produced in a high-tech manufacturing facility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AHN Biotechnologie company profile →
NimbleGen
HQ: United States
Website
- Description: Provider of products and services for the life science research market, offering the SeqCap EZ solution-based capture system that enables exome enrichment in a single test tube, SeqCap EZ libraries covering exome designs, gene panels, and custom content, and SeqCap EZ reagents to maximize workflow.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NimbleGen company profile →
Grundium
HQ: Finland
Website
- Description: Provider of smart, portable digital microscope slide scanners leveraging state-of-the-art mobile technology for medical and research specialists. Offerings include Ocus 20 (20x) for fast imaging, intraoperative frozen sections and general pathology; Ocus 40 (40x) for high-resolution histopathology, tumor grading and cytology; and upcoming Ocus M 40 with four-slide tray, upgraded processor and 2TB storage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grundium company profile →
SynAgile
HQ: United States
Website
- Description: Provider of DopaFuse, a continuous oral infusion therapy designed to stabilize L-DOPA levels for Parkinson’s disease patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynAgile company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nanna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nanna Therapeutics
2.2 - Growth funds investing in similar companies to Nanna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nanna Therapeutics
4.2 - Public trading comparable groups for Nanna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →